UPDATE: Piper Jaffray Downgrades AtriCure from Overweight to Neutral

Piper Jaffray downgraded AtriCure ATRC from an Overweight rating to a Neutral rating and lowered its price target from $12 to $6. Piper Jaffray commented, “While the business at AtriCure performed well during Q2 with revenues of $18.3M (+8.9%, 10.5%cc) exceeding consensus expectations of $18.0M, the surprise and apparently sudden resignation of CEO David Drachman after 10 years at the company was the clear headliner. Considering ATRC was arguably at the brink of a positive inflection point in the company's history, Drachman's departure following the CFO departure last quarter gives us pause. Given the executive departures, suspension of guidance and uncertainty around the near-term direction of the company we downgrade ATRC shares to Neutral and lower our PT to $6 (1.5x EV/CY13E sales of $76M).” AtriCure closed at $8.10 on Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!